JADPRO | Volume 8, Number 7 (Nov/Dec 2017)

Over the past two decades, biologics have had a huge impact on the treatment of cancer in multiple tumor types, and in many cases these agents have improved outcomes and survival. In oncology, a growing number of biosimilars have been approved and are in clinical use, with more in the FDA pipeline.

Editorial

Innovations in Cancer Therapies and Rising Costs

Original Research

Psychosocial Distress as a Factor in Patients With Cancer Seeking Support: A Hermeneutic Study

As the incidence of new cases of cancer increases every year, breaking bad news to patients is very important. The purpose of our study was to explore the lived experiences of Iranian cancer patients about hearing such bad news. This qua...

Review Article

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

Abstract Biosimilar agents are biologic products that have been shown to be “highly similar” to an already approved reference biologic product. Their integration into clinical practice has the potential to significantly decrease costs f...

Review Article

Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies

Abstract Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells. The advent of novel and targeted therapies that have impro...

Grand Rounds

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)

Case Study A male patient aged 67 years with a 2-year history of refractory anemia and myelodysplastic syndromes (MDS) with del(5q) started lenalidomide (Revlimid) treatment as a participant in the MDS-001 trial (List et al., 2005). At ...

Grand Rounds